Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE M VENEREO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144299009
CMS profile
324488
Location
DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$125.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $125.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $125.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE M VENEREO

NPI 1144299009 · CMS profile ID 324488

Allopathic & Osteopathic Physicians / Internal Medicine

DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144299009?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144299009?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144299009?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1144299009?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $125.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $125.0012/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915208697 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34.17 2
PY2020 $83.58 5
PY2021 $95.63 5
PY2022 $125.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $978,346.35 79
PY2024 Principal investigator $750,186.73 535
PY2023 Recipient $250.00 1
PY2023 Principal investigator $1,161,263.89 753
PY2022 Recipient $450.00 1
PY2022 Principal investigator $433,849.06 425
PY2021 Recipient $437.46 1
PY2021 Principal investigator $229,625.48 182
PY2020 Principal investigator $282,764.54 64
PY2019 Principal investigator $543,958.67 209

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

426 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $166.65 12/31/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism No dispute reported 06/30/2026 965539649
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910114901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115581
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115583
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115587
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115589
Principal investigator 1 Alnylam Pharmaceuticals Inc. $23,607.00 12/21/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,672.60 12/21/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115081
Principal investigator 1 GlaxoSmithKline, LLC. $495.00 12/21/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954581
Principal investigator 1 GlaxoSmithKline, LLC. $590.00 12/21/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954591
Principal investigator 1 ABBVIE INC. $262.80 12/15/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889825429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $62.00 12/12/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $56.00 12/12/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $585.00 12/12/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,350.00 12/12/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,020.00 12/12/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 12/12/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115073
Principal investigator 1 Janssen Research & Development, LLC $5,580.00 12/12/2022 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 885221467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $42,242.40 12/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $234.00 12/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,170.00 12/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,564.00 12/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115051
Principal investigator 1 GlaxoSmithKline, LLC. $3,232.57 12/02/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 965505733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910114925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115275
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115289
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115309
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115317
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115537
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115541
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115547
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115553
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115557
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115563
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115565
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115571
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115577
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $244.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $130.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $192.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $220.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,925.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,432.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,468.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 11/23/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $47.25 11/14/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114899
Principal investigator 1 Alnylam Pharmaceuticals Inc. $47.25 11/14/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $793.00 11/07/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,779.30 11/04/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910114993
Principal investigator 1 GlaxoSmithKline, LLC. $2,273.22 11/04/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 965505787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,448.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $122.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $130.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,800.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $128.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $110.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,340.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $738.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21,866.40 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 11/02/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910114913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115239
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910115243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115263
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $585.00 10/19/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910114945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,088.00 10/19/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910114947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $140.00 10/17/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $140.00 10/17/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910115271
Principal investigator 1 ABBVIE INC. $2,739.80 10/12/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889814457
Principal investigator 1 GlaxoSmithKline, LLC. $275.00 10/12/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,561.00 10/05/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,315.00 10/05/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,740.00 10/05/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1) No dispute reported 06/30/2026 910114937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,762.10 10/05/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2) No dispute reported 06/30/2026 910114941
Principal investigator 1 GlaxoSmithKline, LLC. $3,150.90 10/05/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114721
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114735
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114789
Principal investigator 1 GlaxoSmithKline, LLC. $3,083.31 09/22/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954525
Principal investigator 1 GlaxoSmithKline, LLC. $6,091.95 09/01/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954523
Principal investigator 1 GlaxoSmithKline, LLC. $875.16 09/01/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954587
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114695
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114717
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,564.00 08/26/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,924.00 08/26/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $390.00 08/26/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114667
Principal investigator 1 Alnylam Pharmaceuticals Inc. $92.00 08/22/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $408.00 08/22/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114649
Principal investigator 1 ABBVIE INC. $20,827.70 08/10/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889804507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,292.00 08/10/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $175.50 08/05/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114663
Principal investigator 1 GlaxoSmithKline, LLC. $2,784.60 08/01/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114631
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114793
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114861
Principal investigator 1 GlaxoSmithKline, LLC. $875.16 07/20/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954547
Principal investigator 1 GlaxoSmithKline, LLC. $875.16 07/20/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954565
Principal investigator 1 GlaxoSmithKline, LLC. $2,625.48 07/20/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954601
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $600.00 07/15/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 942355309
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $90.00 07/15/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 942355315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $408.00 07/11/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114637
Principal investigator 1 GlaxoSmithKline, LLC. $246.10 07/11/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954521
Principal investigator 1 ABBVIE INC. $673.60 07/07/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889799117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,383.10 07/06/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114661
Principal investigator 1 GlaxoSmithKline, LLC. $11,629.56 07/06/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954531
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 07/06/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114521
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114537
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114541
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114563
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114571
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114581
Principal investigator 1 GlaxoSmithKline, LLC. $1,750.32 06/22/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954571
Principal investigator 1 GlaxoSmithKline, LLC. $875.16 06/22/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954589
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 06/15/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114389
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $780.00 06/10/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 942355297
Principal investigator 1 ABBVIE INC. $1,872.80 06/08/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889794207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $340.00 06/03/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114387
Principal investigator 1 GlaxoSmithKline, LLC. $15,560.45 06/03/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954513
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114477
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114503
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114511
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 05/25/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954597
Principal investigator 1 GlaxoSmithKline, LLC. $605.88 05/25/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954605
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 05/11/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954551
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 05/11/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954553
Principal investigator 1 GlaxoSmithKline, LLC. $605.88 05/11/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954599
Principal investigator 1 ABBVIE INC. $128.00 05/05/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889790043
Principal investigator 1 ABBVIE INC. $3,580.80 05/05/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889790045
Principal investigator 1 GlaxoSmithKline, LLC. $1,654.19 05/04/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954529
Principal investigator 1 Eli Lilly and Company $3,994.00 05/02/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917833195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114589
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114601
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114612
Recipient Eli Lilly and Company $450.00 04/29/2022 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917812357
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,961.20 04/27/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 909413145
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 04/25/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954583
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,500.00 04/22/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,531.00 04/22/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114397
Principal investigator 1 ABBVIE INC. $1,922.40 04/07/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889784287
Principal investigator 1 GlaxoSmithKline, LLC. $989.94 04/06/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954527
Principal investigator 1 GlaxoSmithKline, LLC. $1,692.90 04/06/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954543
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 04/06/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113853
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114263
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114275
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114281
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114289
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114293
Principal investigator 1 ABBVIE INC. $34,521.60 03/29/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism No dispute reported 06/30/2026 889782665
Principal investigator 1 GlaxoSmithKline, LLC. $3,737.69 03/25/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954517
Principal investigator 1 ABBVIE INC. $1,000.00 03/24/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889782537
Principal investigator 1 GlaxoSmithKline, LLC. $908.82 03/23/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954557
Principal investigator 1 GlaxoSmithKline, LLC. $605.88 03/16/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954567
Principal investigator 1 GlaxoSmithKline, LLC. $334.62 03/16/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954579
Principal investigator 1 GlaxoSmithKline, LLC. $2,915.55 03/09/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954539
Principal investigator 1 GlaxoSmithKline, LLC. $1,389.96 03/09/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954541
Principal investigator 1 ABBVIE INC. $2,417.50 03/08/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889779717
Principal investigator 1 ABBVIE INC. $390.00 03/08/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889779727
Principal investigator 1 GlaxoSmithKline, LLC. $8,083.80 03/04/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954509
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114245
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114359
Principal investigator 1 GlaxoSmithKline, LLC. $334.62 02/22/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954537
Principal investigator 1 GlaxoSmithKline, LLC. $1,389.96 02/22/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954563
Principal investigator 1 GlaxoSmithKline, LLC. $2,779.92 02/22/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954577
Principal investigator 1 ABBVIE INC. $128.00 02/17/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889777879
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 02/09/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954555
Principal investigator 1 GlaxoSmithKline, LLC. $3,114.54 02/09/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954569
Principal investigator 1 ABBVIE INC. $4,287.90 02/03/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889775513
Principal investigator 1 GlaxoSmithKline, LLC. $2,652.36 02/02/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910113913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910114213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114303
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114311
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114319
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910114327
Principal investigator 1 Eli Lilly and Company $150.00 01/31/2022 Non-covered Recipient Entity
NECCR PRIMA CARE RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 917834309
Principal investigator 1 GlaxoSmithKline, LLC. $334.62 01/24/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954535
Principal investigator 1 GlaxoSmithKline, LLC. $1,557.27 01/24/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954549
Principal investigator 1 GlaxoSmithKline, LLC. $1,389.96 01/24/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954559
Principal investigator 1 GlaxoSmithKline, LLC. $1,222.65 01/24/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954573
Principal investigator 1 GlaxoSmithKline, LLC. $4,002.57 01/24/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954575
Principal investigator 1 GlaxoSmithKline, LLC. $2,779.92 01/24/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954593
Principal investigator 1 GlaxoSmithKline, LLC. $2,226.51 01/24/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954595
Principal investigator 1 GlaxoSmithKline, LLC. $302.94 01/24/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943954603
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,055.73 01/20/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia No dispute reported 06/30/2026 942355303
Principal investigator 1 ABBVIE INC. $1,669.60 01/06/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889772923
Principal investigator 1 ABBVIE INC. $1,450.81 01/06/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism No dispute reported 06/30/2026 889772925
Principal investigator 1 GlaxoSmithKline, LLC. $32,528.92 01/05/2022 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 943954511
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $200.12 01/01/2022 Non-covered Recipient Entity
Pharmax Research Clinic
Connex 3 No dispute reported 06/30/2026 946886681